NEOBEE M-5 was developed in the 1950s for use in products to treat patients with fat malabsorption syndrome. Derived from the esterification of capric and caprylic fatty acids with glycerin, Neobee M-5 follows a unique metabolic pathway.
Unlike typical long chain triglycerides that travel through the lymphatic system, the ingredient travels directly to the liver. As a result, it is metabolized in 1/8 the time of long chain triacyglycerides and does not accumulate as fat in the body.